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Abstract
Background. Evidence from single and multicenter phase II trials have suggested diffusion MRI is a predictive imaging biomarker for survival benefit in recurrent glioblastoma (rGBM) treated with anti-VEGF therapy. The current
study confirms these findings in a large, randomized phase III clinical trial.
Methods. Patients with rGBM were enrolled in a phase III randomized (1:1), controlled trial (NCT02511405) to
compare the efficacy and safety of bevacizumab (BV) versus BV in combination with ofranergene obadenovec
(BV+VB-111), an anti-cancer viral therapy. In 170 patients with diffusion MRI available, pretreatment enhancing
tumor volume and ADC histogram analysis were used to phenotype patients as having high (>1.24 µm2/ms) or low
(<1.24 µm2/ms) ADCL, the mean value of the lower peak of the ADC histogram, within the contrast enhancing tumor.
Results. Baseline tumor volume (P = .3460) and ADCL (P = .2143) did not differ between treatment arms. Univariate
analysis showed patients with high ADCL had a significant survival advantage in all patients (P = .0006), as well as
BV (P = .0159) and BV+VB-111 individually (P = .0262). Multivariable Cox regression accounting for treatment arm,
age, baseline tumor volume, and ADCL identified continuous measures of tumor volume (P < .0001; HR = 1.0212)
and ADCL phenotypes (P = .0012; HR = 0.5574) as independent predictors of OS.
Conclusion. Baseline diffusion MRI and tumor volume are independent imaging biomarkers of OS in rGBM treated
with BV or BV+VB-111.
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Key Points
• Pretreatment volume and ADC were significant predictors of overall survival in
rGBM treated with anti-VEGF treatment.

Importance of the Study
Bevacizumab, an antiangiogenic drug and the
U.S. standard of care for rGBM, has demonstrated a PFS benefit, but has not shown an advantage in OS. Overwhelming evidence from
single center and multicenter phase II data
suggests patients with a higher apparent diffusion coefficient (ADC) within their tumors
have a significant OS benefit when treated with
anti-VEGF therapy, including bevacizumab.
The current study validates this observation

Despite promising initial data and widespread exploration of anti-VEGF therapies in recurrent GBM, randomized
phase II trials have not demonstrated an overall survival
(OS) benefit for all patients with recurrent GBM.1–3 We have
demonstrated retrospectively in both single center4–7 and
multicenter phase II trials8–10 that recurrent GBM patients
with distinct diffusion MR imaging features have a significant survival benefit when treated with bevacizumab. We
have demonstrated that measurements of the apparent
diffusion coefficient (ADC) within the area of contrast enhancement on T1-weighted images can be modeled using
a double Gaussian mixed model where ADCL is the mean
value of the lower Gaussian distribution, reflecting the
more densely cellular component of the tumor, and ADCH
is the mean value of the higher Gaussian distribution, more
representative of tumor tissue containing more necrosis,
edema, or cerebrospinal contamination (Figure 1B–G).
Data in rGBM treated with a wide range of anti-VEGF therapies (eg, cediranib [NCT00035656]; bevacizumab (BRAIN
Trial, AVF3708g; NCT00345163); cabozantinib (XL184-201;
NCT00704288); and aflibercept (VEGF Trap; NCT00369590)
suggests patients with tumors exhibiting an ADCL higher
than 1.24 µm2/ms on pretreatment diffusion MR images
have a significant survival benefit compared with patients
who have a lower ADCL, even after controlling for known
prognostic variables including age and baseline tumor
size.8 This was independently confirmed8 using data from
BELOB,3 which showed ADCL and tumor volume to be predictive for patients treated with bevacizumab monotherapy,
but not single agent lomustine. Furthermore, a recent posthoc analysis of the EORTC-26101 trial by Schell et al.11 confirmed our findings, showing that ADCL using a threshold of
1.24 µm2/ms is prognostic for both progression-free survival
(PFS) and OS in rGBM patients treated with bevacizumab
(10.4 vs 8.1 months median OS, P = .0004).

in a randomized, controlled phase III trial
of rGBM treated with bevacizumab with or
without VB-111, a novel antiangiogenic treatment. Results suggest diffusion MRI, which is
recommended as part of the standardized brain
tumor imaging protocol, may be a valuable
tool for determining survival benefit in rGBM
patients considering bevacizumab or other
antiangiogenic therapies.

Ofranergene obadenovec (VB-111),12,13 a viral gene therapy
that triggers apoptosis of tumor vascular endothelium, is a
novel antiangiogenic therapy and an alternative to traditional
anti-VEGF therapies. Phase II studies of VB-111 have shown to
increase survival in rGBM when used prior to treatment with
bevacizumab.13 In the current study, we examine whether
diffusion MR imaging phenotypes in tumors included in
the GLOBE trial,12 a randomized controlled phase III study
of VB-111 combined with bevacizumab versus bevacizumab
monotherapy in patients with recurrent glioblastoma.12
Using this study, we aim to further validate the ability of diffusion MR phenotypes to predict survival in patients treated
with bevacizumab as well as combined antiangiogenic
therapy consisting of bevacizumab and VB-111.

Methods
Study Objectives
This study was approved by UCLA institutional review
board (#10-000655; #14-001261). We retrospectively reviewed clinical, imaging, and survival data from a phase
III randomized (1:1), controlled trial (NCT02511405)
aimed to compare efficacy of bevacizumab alone versus
bevacizumab with ofranergene obadenovec (VB-111) in recurrent glioblastoma to determine whether diffusion MRI
and other factors were independent prognostic factors
for OS.

Patient Eligibility
Eligible participants were adults aged >18 years with first
or second progression of histologically confirmed GBM,
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• Patients with a high ADC prior to bevacizumab +/- VB-111 have 2–3 months
additional median survival (HR = 0.55).
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Figure 1. Study schema and ADC histogram analyses for representative rGBM patients. (A) Study schema showing initial study size (N = 256), for
which 84 patients were excluded for lack of high-quality pretreatment diffusion MRI data (73 missing data and 11 with significant artifacts), leaving
N = 172 patients for this imaging sub study. Of these 172 patients, N = 80 were randomized to the bevacizumab monotherapy arm (BV) and 92 were
randomized to the combination of VB-111 and bevacizumab (VB+BV). (B) Post-contrast T1-weighted, (C) apparent diffusion coefficient (ADC) map,
and (D) ADC histograms for a patient with low ADCL, or high risk (ADCL = 0.97 µm2/ms). (E) Post-contrast T1-weighted, (F) ADC map, and (G) ADC histograms for a patient with high ADCL, or low risk (ADCL = 1.53 µm2/ms).
  

who had received previous treatment with standard of care
radiotherapy and temozolomide. Additionally, patients
needed to have a KPS of at least 70%, life expectancy of
at least 3 months, an interval of at least 12 weeks since
the cessation of radiotherapy, and measurable lesion by
RANO.28 Exclusion criteria included prior antiangiogenic
therapy, history of recent grade 2 or higher CNS hemorrhage, gastrointestinal bleeding or pulmonary hemorrhage/hemoptysis, inherited bleeding diathesis or
significant coagulopathy at risk of bleeding, surgical treatment or significant trauma within 4 weeks, active vascular
disease, proliferative and/or vascular retinopathy, inadequately controlled hypertension, history of gastrointestinal
perforation or abscess.

Study Design
This was a phase III multisite, international, randomized,
open-labeled, controlled trial. Study design and treatment
regimens were determined in agreement with an FDA
Special Protocol Assessment (SPA). Eligible patients with
rGBM were randomized 1:1 to receive either VB-111 1 ×

1013 VPs every 8 weeks in combination with bevacizumab
10 mg/kg every 2 weeks (VB+BV) or bevacizumab monotherapy 10 mg/kg every 2 weeks (BV). Treatment assignment was determined by central randomization, and was
stratified by age, KPS and first or second progression.
Disease characteristics, including local assessment of the
prognostic factors MGMT Methylation, EGFRvIII and IDH-1
mutation, were collected from patients’ medical history (if
available). Primary endpoint was OS, defined as the time
from randomization until death from any cause.
Upon evidence of PD by RANO (defined as ≥25% increase
in the sum of enhancing lesions diameters) continuation or discontinuation of study therapy was decided per
physician’s discretion, as long as the patient did not have
increase in tumor measurements >50% or any confirmed
T2/FLAIR and/or clinical deterioration. All patients who discontinued study drug were treated according to standard
of care, and there was no cross-over from bevacizumab
monotherapy to VB-111. All efforts were made to collect
post-study MRIs, health related quality of life measures,
follow-up of anti-cancer treatments and survival data every
2–3 months until the patient expired. Dose reductions of
VB-111 and bevacizumab were not allowed. Repeat VB-111
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Magnetic Resonance Imaging
For the current study, only baseline (pretreatment) MRI
scans were used. All MRI scans were obtained on a 1.5T
or 3T MR scanner and were compliant with the standardized brain tumor imaging protocol,14 including 1–1.5 mm
isotropic pre- and post-contrast T1-weighted images,
T2-weighted turbo spin echo and T2-weighted FLAIR images, and diffusion-weighted images with at least b = 0 and
1000 s/mm2 and slice thickness ≤4 mm.

Statistical Analysis
All analysis was carried out in MATLAB or using GraphPad
Prism v9.0.1 (GraphPad Software). Baseline volume and
ADCL were compared using unpaired t-tests. Overall survival between different diffusion phenotypes as well as
between different treatment groups were evaluated using
cox regression survival analysis. Multivariate cox regression analysis including age, pretreatment tumor volume,
ADCL, and treatment arm was carried out to evaluate independent predictors of overall survival. P values of < 0.05
were considered significant.

Results

T1 Subtraction Maps
Contrast enhanced T1-weighted digital subtraction maps
were used to insulate areas of contrast enhancement and
exclude blood products and necrotic regions within the
tumor using previously described techniques.15–17 Briefly,
T1-weighted images with and without contrast were
co-registered, intensity normalized, then subtracted from
each other on a voxel-wise basis to highlight the change
in signal intensity due to contrast administration. Regions
with positive values were segmented and used for ADC
histogram analysis.

ADC Histogram Analysis
ADC histogram analysis was applied using standard
techniques described elsewhere.4,6,8,9,18 Simply, histograms were generated from ADC values extracted from contrast enhancing regions from T1
subtraction maps were generated, with average histogram bin size of 0.05 µm2/ms. Then, nonlinear regression was performed using a double Gaussian model defined
as: p(ADC = f  N (ADCL , σADCL ) + (1 − f ) N(ADCH , σADCH ),
where p(ADC) is the probability of a specific ADC value,
f is the proportion of voxels in the histogram, N(μ,σ) is a
  
Table 1.

normal Gaussian distribution with mean = μ and standard
deviation = σ, and ADCL is mean of the lower Gaussian distribution and ADCH is mean of the higher Gaussian distribution. From this, ADCL was used for further analyses.

A total of 172 of the original 256 patients with recurrent
glioblastoma enrolled in the phase III randomized controlled trial (NCT02511405) had available pretreatment
diffusion imaging and were included in this study (Figure
1A). Of these patients, 92 of original 128 patients were
randomized to VB+BV and had adequate diffusion imaging available (32 missing diffusion data and 4 with significant artifacts by quality control procedures described
previously19), while 80 of the original 128 patients were
randomized to BV and had adequate imaging available
(41 missing diffusion data and 7 with significant artifacts).
Table 1 highlights the patient characteristics for patients
included in the current study. Figure 1B–G illustrates representative patients with low and high ADCL. There was
no significant difference in mean pretreatment contrast
enhancing tumor volume between the 2 groups (Figure
2A; t-test, P = .3460; BV, mean volume = 26.2 mL; range
18.7–128.1 mL; VB+BV, mean volume = 23.0 mL; range
19.3–88.5 mL) Similarly, pretreatment ADCL values were
not significantly different between the 2 groups (Figure
2B; t-test, P = 0.2143; BV, mean ADCL = 1.28 µm2/ms;
range 0.78–3.03 µm2/ms; VB+BV, mean ADCL = 1.23 µm2/
ms; range 0.64–1.94 µm2/ms). MGMT promoter methylation status was evenly split between ADCL high and low

Patient Characteristics for Imaging Sub Study of GLOBE Trial
VB-111 + Bevacizumab

Bevacizumab

Characteristics

(VB+BV) (N = 92)

(BV) (N = 80)

P-Value

Mean age, y (SD)

55.1 (11.3)

54.4 (13.1)

.7072

Male (%)

60 (65%)

55 (69%)

Female (%)

32 (35%)

25 (31%)

Baseline KPS (SD)

83 (9.5)

84 (9.3)

.4878

Median Survival (Months)

6.4

7.9

.3471

Sex
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dosing was delayed for patients who experienced a drug
related AE, until the severity of the event was no more than
CTCAE Grade 1. All patients received concomitant predose acetaminophen to mitigate post-treatment fever, and
pre-dose dexamethasone (10 mg) followed by 4 mg twice
daily for 3 days post-dosing to prevent potential cerebral
edema.
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Figure 2. Baseline tumor volume and diffusion MRI measurements. (A) Comparison of pretreatment, baseline enhancing tumor volume (P = .3460)
and (B) ADCL (P = .2143) between BV and VB+BV treatment arms showing no significant differences.
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Figure 3. Overall survival comparisons between treatment arms and diffusion characteristics. Kaplan–Meier plots showing higher overall survival
in rGBM with ADCL > 1.24 µm2/ms compared with ADCL < 1.24 µm2/ms when examining (A) all patients (Log-rank, P = .0006), (B) patients in the BV
arm (Log-rank, P = .0159), and (C) patients in the VB+BV arm (Log-rank, P = .0262). No significant difference between treatment groups was observed when looking within tumors exhibiting (D) ADCL > 1.24 µm2/ms (Low Risk; Log-rank, P = .5743) or (E) ADC < 1.24 µm2/ms (High Risk; Log-rank,
P = .4609). (F) Comparison of survival between diffusion MR phenotypes and treatment groups, showing a significant trend (Log-rank test for trends,
P = .0209).
  

(20 vs 17 methylated, 34 vs 46 unmethylated, and 28 vs
27 missing or unknown). Similarly, IDH mutation status
was also evenly distributed between ADCL high and low
phenotypes (10 vs 12 mutated, 56 vs 58 wild type, 16 vs 20
missing or unknown.

Pretreatment diffusion phenotypes as stratified by ADCL
greater than or less than 1.24 µm2/ms were significantly
associated with survival. Specifically, high ADCL (ADCL >
1.24 µm2/ms) was associated with increased overall survival relative to patients with low pretreatment ADCL
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Discussion
Identifying effective therapies in recurrent GBM remains
one of the most difficult challenges in neuro-oncology.
Given that these patients may often not be eligible for repeat debulking surgery, personalized treatment strategies
in the recurrent setting are significantly limited because of
lack of tissue biomarkers to inform decision-making. While
some molecular markers such as MGMT methylation
status and IDH mutational harbor prognostic implications,
these have a limited role in the setting of recurrent GBM
and specifically in the setting of salvage therapies like antiVEGF therapies. Thus, a pretreatment imaging biomarker
that can be used to guide treatment decisions in rGBM is
greatly desired. Results from the current study strongly
support previous single institution4–7 and multicenter
phase II trials8–11 showing that ADCL, using a threshold of
1.24 µm2/ms, within contrast enhancing tumor is an independent imaging biomarker for predicting overall survival
  
Table 2.

benefit from anti-VEGF treatments, including combination
therapies.
Whether diffusion MR phenotypes are predictive for antiVEGF treatment or merely prognostic for all treatments
in rGBM is still open to considerable debate. Previous
single institution studies have suggested that diffusion
MR phenotypes are predictive for survival benefit in antiVEGF monotherapy, but not cytotoxic chemotherapies4 or
surgical resection.7 This was independently confirmed8 in
a separate cohort using data from BELOB,3 which showed
ADCL to be predictive for patients treated with bevacizumab
monotherapy, but not single agent lomustine. When this
was tested post-hoc using data from EORTC-26101, Schell
et al.11 found that ADCL using a similar threshold was prognostic for both bevacizumab and non-bevacizumab treated
patients. However, unlike previous studies,4,8 35% of these
“non-bevacizumab” patients crossed over and received
bevacizumab treatment after disease progression, suggesting diffusion MR phenotypes may still be predictive to
anti-VEGF treatment. Regardless, all these studies harmonize and together strongly support the hypothesis that pretreatment ADCL is a powerful tool for identifying patients
that will have a favorable outcome to anti-VEGF treatment,
including bevacizumab.
The biological basis of these diffusion MR phenotypes
has also been under recent investigation.5,20 Specifically,
we have noted that ADCL is significantly correlated with
increased DNA, RNA, and protein expression of decorin,
a small proteoglycan that both modulates angiogenesis and alters viscosity of the extracellular matrix, and
this relationship is preserved in patient derived xenograft (PDX) models.5 Data suggest decorin may be a multifaceted antiangiogenic agent,21–24 as it interferes with
thrombospondin-1,25 suppress endogenous tumor cell
production of VEGF22,26 and VEGF-A,27 the therapeutic targets of bevacizumab, and binds with a high affinity to
VEGFR1/2.28 Decorin also concurrently modulates the
stiffness of the extracellular matrix by binding with various macromolecules and activating specific matrix
metalloproteinases (MMPs),22 which may explain the relationship between increased decorin expression and increased ADCL, a measure of water mobility (or viscosity)
within the tumor tissue. Studies aimed at identifying any
causal associations between decorin expression, diffusion MR phenotypes, and anti-VEGF efficacy are yet to be
conducted.
In addition, the molecular status of the tumor may also
contribute to the specific diffusion MR phenotypes. For example, a TCGA study by Wu et al.29 suggested that newly
diagnosed IDH mutant gliomas have significantly higher
average ADC values within areas of bulk tumor compared

Cox Multivariate Regression Results for Age, Treatment, Tumor Volume, and ADCL

Variable

Coefficient

Hazard Ratio (HR) [95% CI]

Age (years, continuous)

−0.0086

0.9914 [0.9765–1.0066]

.2660

Treatment (BV vs VB+BV)

0.1271

1.1356 [0.8042–1.6036]

.4702

0.0209

1.0212 [1.0122–1.0302]

<.0001

−0.5844

0.5574 [0.3913–0.7940]

.0012

Tumor Volume (mL, continuous)
ADCL Phenotype (High/Low)

  

P-Value
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when pooling all patients (Figure 3A; Log-rank, P = .0006;
HR = 0.5726; median OS = 8.4 vs 6.2 months). The association of increased overall survival with high ADCL held true
when examining patients within the BV (Figure 3B; Logrank, P = .0159; HR = 0.5513; median OS = 8.7 vs 6.4 months)
and VB+BV combination cohorts (Figure 3C; Log-rank,
P = .0263; HR = 0.6175; median OS = 7.4 vs 5.7 months).
In patients with high ADCL, which has been associated with higher overall survival in anti-VEGF treatment,
there was no difference in overall survival by treatment
strategy (Figure 3D; Log-rank, P = .5743; BV median
OS = 8.7 months vs VB+BV median OS = 7.4 months).
Similarly, in patients with low ADCL, which is associated with lower overall survival when treated with
anti-VEGF therapies, there was no difference in overall
survival by treatment strategy (Figure 3E; Log-rank,
P = .4609; BV median OS = 6.5 months vs VB+BV median OS = 5.7 months). Overall, when comparing 4 distinct groups: (1) high ADCL & BV, (2) low ADCL & BV, (3)
high ADCL & VB+BV, and (4) low ADCL & VB+BV there
was a significant trend in survival outcomes (Figure 3F;
Log-rank test for trends, P = .0209), likely dominated by
diffusion phenotypes rather than treatment strategy.
A multivariable cox regression accounting for treatment arm, age, baseline tumor volume, and ADCL identified continuous measures of tumor volume (Table 2;
P < .0001; HR = 1.0212) and ADCL phenotypes (Table 2;
P = .0012; HR = 0.5574) as independent predictors of
overall survival.

Ellingson et al. A diffusion MR imaging biomarker for bevacizumab +/- VB-111

Results from the current phase III trial confirms that pretreatment contrast enhancing tumor volume and diffusion
MR imaging phenotypes are independent predictors of
overall survival in rGBM treated with bevacizumab with
or without VB-111. Additionally, results suggest clinicians
should consider using diffusion measurements within the
enhancing tumor prior to bevacizumab treatment in order
to estimate potential patient benefits.

Keywords
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